Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
GIMI-IRB-17015
Phase 2 mab active
Quick answer
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells for Acute Myeloid Leukemia is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- mab
- Status
- active